Press Releases
March 8,
2023
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
December 12,
2022
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
November 14,
2022
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
In The News
Tricking the Virus with a Protein Could Prevent Covid-19
ARA. December 12, 2020
Animal Tests Reveal Synthetic Decoy Protein Protects Against Coronavirus
Chemistry World. Dec. 7, 2020
Antibodies Good. Machine-Made Molecules Better?
The New York Times. Nov. 21, 2020
How One Company Pivoted From Cancer To Coronavirs And Designed A Virus-Blocking Drug In 10 Weeks Forbes.com. Nov. 19, 2020
Scientists Advance on One of Technology’s Holy Grails
The New Yorker. Sept. 18, 2020
Neoleukin emerges with a de novo approach to improving biologics
BioCentury – Emerging Company Profile, July 18 2019
If you build it, they will come: Reaching across the “IL” with Neo-2/15
ScienceImmunology, March 1, 2019
Neoleukin-2/15 – A Novel Immunotherapy Agent Designed to Avoid Common Side Effects
OncoZine, Jan. 16, 2019
Neoleukin Therapeutics Hopes to Improve on Nature's Approach to Battling Cancer
BioSpace, Jan. 11, 2019
Scientists design protein that prods cancer-fighting T-cells
University of Washington Medicine Newsroom, Jan. 10, 2019
New Protein Designed that Mimics IL-2 without Severe Side Effects
Genetic Engineering & Biotechnology News, Jan. 10, 2019
Researchers redesign a cancer-busting protein—without the side effects
Science, Jan. 9, 2019
New Seattle startup emerges from UW to develop cancer-fighting protein three decades in the making
GeekWire, Jan. 9, 2019